These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18394266)

  • 1. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia.
    Krivoshiev S; Todorov VV; Manitius J; Czekalski S; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 May; 24(5):1407-15. PubMed ID: 18394266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R; Bhaduri S; Singh AK;
    Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.
    Pergola PE; Gartenberg G; Fu M; Wolfson M; Rao S; Bowers P
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1731-40. PubMed ID: 19808215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.
    Haag-Weber M; Eckardt KU; Hörl WH; Roger SD; Vetter A; Roth K
    Clin Nephrol; 2012 Jan; 77(1):8-17. PubMed ID: 22185963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
    Fishbane S; Singh B; Kumbhat S; Wisemandle WA; Martin NE
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1204-1214. PubMed ID: 29921734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.
    Azmandian J; Abbasi MR; Pourfarziani V; Nasiri AA; Ossareh S; Ezzatzadegan Jahromi S; Sanadgol H; Amini S; Shahvaroughi Farahani A
    Am J Nephrol; 2018; 48(4):251-259. PubMed ID: 30253403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of once-weekly epoetin alfa.
    Barre P; Reichel H; Suranyi MG; Barth C
    Clin Nephrol; 2004 Dec; 62(6):440-8. PubMed ID: 15630903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
    Biggar P; Ketteler M; Hennemann H; Dömling R
    Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.